Breast Cancer Drugs Serve a New Master: The Clinical Pathway
Any company marketing a drug in the United States knows the drill: good access depends on preferred formulary placement and avoiding onerous prior... In DRG Blog/ June, 2019 71% of surveyed MCOs have outcomes-based contracts with pharma or plan to by the end of 2019
Outcomes-based contracting (OBC) is a growing value-based purchasing strategy used by U.S. healthcare payers to hold pharmaceutical... In DRG Blog, Market Access/ January, 2019 How Common is In-Office Dispensing of Oral Prostate Cancer Drugs?
The growing trend of physicians dispensing of oral oncolytics directly to patients disrupts the U.S. reimbursement system’s traditional... In DRG Blog, Market Access/ September, 2018 How will Health Insurers Control the Rising Costs of HR+/HER2- Breast Cancer Drugs?
Key finding: Confronted with the premium price of targeted therapies treating hormone receptor-positive (HR+), human epidermal growth factor... In DRG Blog, Market Access/ August, 2018 Which Factors Will Drive Preferred Reimbursement of SLE Therapies for U.S. Payers?
Key finding: Head-to-head trial data demonstrating a drug is at least as efficacious as Benlysta – the only targeted therapy approved for... In DRG Blog, Market Access/ May, 2018 Physician-administered Lung Cancer Drugs Face Insurer Scrutiny
The relative ease of getting a physician-administered drug in a doctor’s office or hospital is starting to fray as new economic realities change... In DRG Blog, Market Access, Drug Watch/ June, 2016 Sovaldi’s Legacy: Putting a Price on Drug Effectiveness
This morning on ABC news, famed former Baywatch star Pamela Anderson was beaming as she announced she had been cured of Hepatitis C, relieving her... In DRG Blog, Market Access, Drug Watch/ January, 2016 California plans on notice: drug lists will be standardized
When Covered California first opened for business in 2014, comparing qualified health plans by the drugs they cover was an exercise in frustration... In DRG Blog, Market Access, Drug Watch/ October, 2014 The biosimilar train leaves the station, only to face an uphill climb
Faced with the onslaught of high-cost specialty drugs?a reality brought to the fore by the high-priced hepatitis C drug Sovaldi?many plan sponsors... In DRG Blog, Market Access, Drug Watch/ August, 2014 Hep C wonder drug gets the movers shaking
You know a pill is powerful when it brings the nation's healthcare leaders into one room to debate its broad implications for U.S. health policy... In DRG Blog, Market Access, Drug Watch/ May, 2014 Can branded asthma drugs breathe easily on the exchanges?
With 2014 approaching the halfway mark, health plans are already turning their attention to next year's qualified health plans?and that means... In DRG Blog, Market Access, Drug Watch/ May, 2014 Looming healthcare tax lights a fire under corporate America
Listening to the nation's largest employers share their anxieties and strategies over the rising cost of healthcare at the National Business Group... In DRG Blog, Market Access, Drug Watch/ March, 2014 Obama plea puts state-run exchanges in a quandary
Extending cancelled individual insurance policies for another year may seem appropriate for states where the federal government has taken over and... In DRG Blog, Market Access, Drug Watch/ November, 2013 Digging for drugs and docs in Covered California is no easy task
More than two weeks into open enrollment, shoppers in the Covered California insurance exchange lack access to two critical pieces of information... In DRG Blog, Market Access, Drug Watch/ October, 2013 Private exchanges and PBMs friend or foe
Recent news of high-profile companies moving employers to private insurance exchanges has pressured the share prices of publicly traded pharmacy... In DRG Blog, Market Access, Drug Watch/ September, 2013 Anthem's pull-out of SHOP puts nation's largest exchange in spotlight
Anthem Blue Cross's absence from the California small-business health insurance exchange is curious on many levels. Why would one of the state's... In DRG Blog, Market Access, Drug Watch/ August, 2013 Covered California rates hinge on smaller networks
Now that the curtain has lifted on Covered California, potential customers of the insurance marketplace can breathe a bit easier. The premiums... In DRG Blog, Market Access, Drug Watch/ June, 2013 CalPERS decision could shake up California market
As health reform starts in earnest in 2014, health plans in California will not only be jockeying for insurance exchange members but also for the... In DRG Blog, Market Access, Drug Watch/ April, 2013